Isomorphic Labs Advances AI-Designed Cancer Drug Toward Human Trials
Apr 26, 2026
Isomorphic Labs said one AI-designed drug, ISM8969, has FDA clearance for human clinical trials. The company’s initial pipeline focuses on oncology candidates.
News Related to Isomorphic Labs
Related coverage linked through entity extraction aliases.
Novartis CEO Vas Narasimhan joins Anthropic board
Apr 16, 2026
Novartis chief executive Vas Narasimhan has joined Anthropic’s board. The appointment adds a pharma executive as Anthropic expands into drug discovery and launches Claude for Life Sciences.
Pharmaceutical Industry Shifts to Fewer, Larger AI-Driven Drug Development Partnerships
Mar 19, 2026
Global pharmaceutical R&D deal values surged 49% to $86.7 billion in 2025 as companies concentrate investments in AI-powered drug discovery platforms, with average deal sizes reaching a record $1.16 billion despite fewer total partnerships.
Isomorphic Labs Unveils Proprietary AI Drug Discovery Model IsoDDE
Feb 28, 2026
Isomorphic Labs released a 27-page technical report on IsoDDE, its new AI drug-discovery engine that outperforms existing models in predicting drug-protein interactions and antibody structures, but the proprietary system offers limited technical details.
Google DeepMind Unveils IsoDDE Drug Discovery Engine, Updates Gemini Deep Think
Feb 13, 2026
Isomorphic Labs introduced IsoDDE, a drug discovery engine that outperforms AlphaFold 3 by a factor of two in prediction accuracy. Google also updated Gemini 3 Deep Think, which now outperforms competing models in complex scientific tasks.